Current prostate cancer diagnostics are inadequate - they lack sensitivity and prognostic value. Cellanyx is offering a predictive, sensitive, and cost effective solution to inform physicians at the radical prostatectomy decision point. Cellanyx's technology will improve the diagnostic process, increasing patient quality of life - significantly reducing health care costs.

2012 Boston Silver Winner